+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults



A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults



Critical Care Medicine 43(8): 1622-1629



To determine whether regional anticoagulation of continuous renal replacement therapy circuits using citrate and calcium prolongs circuit life and/or affects circulating cytokine levels compared with regional anticoagulation using heparin and protamine. Multicenter, parallel group randomized controlled trial. Seven ICUs in Australia and New Zealand. Critically ill adults requiring continuous renal replacement therapy. Patients were randomized to receive one of two methods of regional circuit anticoagulation: citrate and calcium or heparin and protamine. The primary outcome was functional circuit life measured in hours, assessed using repeated events survival analysis. In addition, we measured changes in interleukin-6, interleukin-8, and interleukin-10 blood levels. We randomized 212 subjects who were treated with 857 continuous renal replacement therapy circuits (median 2 circuits per patient [interquartile range, 1-6], 390 in citrate group vs 467 in heparin group). The groups were well matched for baseline characteristics. Patients receiving regional continuous renal replacement therapy anticoagulation with heparin and protamine were more likely to experience circuit clotting than those receiving citrate and calcium (hazard ratio, 2.03 [1.36-3.03]; p < 0.0005; 857 circuits). The median lifespan of the first study circuit in each patient was 39.2 hours (95% CI, 32.1-48.0 hr) in the citrate and calcium group versus 22.8 hours (95% CI, 13.3-34.0 hr) in the heparin and protamine group (log rank p = 0.0037, 204 circuits). Circuit anticoagulation with citrate and calcium had similar effects on cytokine levels compared with heparin and protamine anticoagulation. There were more adverse events in the group assigned to heparin and protamine anticoagulation (11 vs 2; p = 0.011). Regional citrate and calcium anticoagulation prolongs continuous renal replacement therapy circuit life compared with regional heparin and protamine anticoagulation, does not affect cytokine levels, and is associated with fewer adverse events.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057040681

Download citation: RISBibTeXText

PMID: 25853591

DOI: 10.1097/ccm.0000000000001004


Related references

Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Critical Care 20(1): 144, 2016

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. Bmj Open 9(1): E024411, 2019

Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. American Journal of Kidney Diseases 59(6): 810-818, 2012

Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care and Resuscitation 16(2): 131-137, 2014

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International 67(6): 2361-2367, 2005

2% Trisodium citrate regional anticoagulation versus systemic heparin anticoagulation in continuous renal replacement therapy A retrospective study. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 328A, 2000

Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation 26(1): 232-239, 2011

Sp241Simplified Regional Citrate Anticoagulation Using A Calcium-Containing Replacement Solution For Continuous Renal Replacement Therapy: A Randomized Prospective Pilot Trial. Nephrology Dialysis Transplantation 33(Suppl_1): i424-i425, 2018

Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice. Journal of the Intensive Care Society 18(3): 184-192, 2017

Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. Journal of Critical Care 20(2): 155-161, 2005

Continuous renal replacement therapy with regional citrate anticoagulation in critically ill children. Blood Purification 13(6): 387, 1995

Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy. Nursing in Critical Care 14(4): 191-199, 2009

Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation. Critical Care Medicine 45(9): E941-E946, 2017

Clinical impact of regional citrate anticoagulation in continuous renal replacement therapy in critically ill patients. International Journal of Artificial Organs 40(12): 676-682, 2017

Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Medicine 38(1): 20-28, 2012